Loading data for PTHS — first visit, this takes a few seconds.
Pelthos Therapeutics Inc.
19.42 -0.90 (-4.43%)
18.92 -2.57%
- Market Cap
- $74.35M
- Volume
- 63.5K
- Dividend yield
- n/a
- Next earnings date
- Nov 12, 2026
Pelthos Therapeutics Inc. (PTHS) Stock Price, Analysis & Data
Intrinsic Value
Analyst Forecast
Stock Forecasts →Latest Earnings
| Reported | Vs estimate | YoY Change | |
|---|---|---|---|
| Revenue | $15.60M | n/a | n/a |
| EPS | -$3.79 | -$0.84 | +29.55% |
Metrics
- Bid
- 7.84
- Market Cap
- 74.3M
- Revenue (ttm)
- 43.3M
- Net Income (ttm)
- -86.4M
- 3.05
- -27.36
- n/a
- -3.42
- P/B (ttm)
- -48.07
- P/S (ttm)
- 1.72
- Earnings Date
- Nov 12, 2026
- Ask
- 24.83
- Volume
- 63,518
- Avg. Volume (20D)
- 59,766
- Open
- 20.29
- Previous Close
- 20.32
- Day's Range
- 18.20 - 21.00
- 52-Week Range
- 18.19 - 37.50
- Analyst
- n/a
- Price Target
- n/a
- Dividends
- n/a
- Ex-Dividend Date
- n/a
About Pelthos Therapeutics Inc.
View profile →Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE, a pediculicide indicated for topical treatment of head lice infestation in patients 6 months of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025. Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina.
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE, a pediculicide indicated for topical treatment of head lice infestation in patients 6 months of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025. Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina.
Industry Biotechnology
Sector Healthcare
IPO Date Feb 16, 2024
Employees 92
Stock Exchange NYSE American
Ticker Symbol PTHS
Website https://pelthos.com